Overview

The Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients.

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Inflammation is important in the both pathogenesis and outcome of atherosclerosis. Plaques containing numerous inflammatory cells, particular macrophages, have a high risk of rupture.We hypothesize that statin-induced plaque regression could be monitored clinically by use of FDG PET/CT approach, and can be detected noninvasively earlier than previously reported.
Phase:
N/A
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborators:
National Science Council, Taiwan
Pfizer
Treatments:
Atorvastatin
Atorvastatin Calcium